Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2014

Open Access 01-12-2014 | Research article

Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: a cross-sectional study

Authors: Nam Soo Hong, Jeong-Gook Kim, Yu-Mi Lee, Hyun-Woo Kim, Sin Kam, Keon-Yeop Kim, Ki-Su Kim, Duk-Hee Lee

Published in: BMC Endocrine Disorders | Issue 1/2014

Login to get access

Abstract

Background

Despite the consistent relationship between serum γ-glutamyltransferase (GGT) and type 2 diabetes (T2D), one unsolved issue is the role of serum GGT in the well-known association between obesity and T2D. This study was performed to investigate whether the association between body mass index (BMI) and impaired fasting glucose (IFG) differed depending on serum GGT levels within the normal range.

Methods

Study subjects were 2,424 men and 3,652 women aged ≥ 40, participating in the Fifth Korean National Health and Nutrition Examination Survey. Serum GGT levels within the normal range were classified into gender-specific tertiles.

Results

Among men and women belonging to the lowest tertile of serum GGT, BMI showed statistically non-significant weak associations with the risk of IFG. However, among persons in the highest tertile of serum GGT, the risk of IFG was 3 − 4 times higher among persons with BMI ≥ 25 kg/m2 than those with BMI < 23 kg/m2 (Pinteraction = 0.032 in men and 0.059 in women).

Conclusions

The well-known strong association between BMI and IFG was observed mainly among persons with elevation of serum GGT to certain physiological levels, suggesting a critical role of serum GGT in the pathogenesis of IFG. This finding has an important clinical implication because serum GGT can be used to detect high-risk obese persons.
Appendix
Available only for authorised users
Literature
1.
go back to reference Andre P, Balkau B, Born C, Charles MA, Eschwege E: Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia. 2006, 49: 2599-2603.CrossRefPubMedPubMedCentral Andre P, Balkau B, Born C, Charles MA, Eschwege E: Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia. 2006, 49: 2599-2603.CrossRefPubMedPubMedCentral
2.
go back to reference Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y: Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012, 20: 842-848.CrossRef Onat A, Can G, Ornek E, Cicek G, Ayhan E, Dogan Y: Serum gamma-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012, 20: 842-848.CrossRef
3.
go back to reference Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomileto J: Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004, 89: 5410-5414.CrossRefPubMed Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomileto J: Gamma-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004, 89: 5410-5414.CrossRefPubMed
4.
go back to reference Perry IJ, Wannamethee SG, Shaper AG: Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998, 21: 732-737.CrossRefPubMed Perry IJ, Wannamethee SG, Shaper AG: Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998, 21: 732-737.CrossRefPubMed
5.
go back to reference Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, Blomhoff R, Jacobs DR: Gamma-glutamyltransferase and diabetes–a 4 year follow-up study. Diabetologia. 2003, 46: 359-364.CrossRefPubMed Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, Blomhoff R, Jacobs DR: Gamma-glutamyltransferase and diabetes–a 4 year follow-up study. Diabetologia. 2003, 46: 359-364.CrossRefPubMed
6.
go back to reference Shin JY, Hwang JH, Jeong JY, Kim SH, Moon JD, Roh SC, Kim YW, Kim Y, Leem JH, Ju YS, Hong YS, Ha EH, Lee YH, Kim DH, Lee DH: The association of central obesity with type 2 diabetes among Koreans according to the serum gamma-glutamyltransferase level: Korean genome and epidemiology study. J Prev Med Public Health. 2009, 42: 386-391.CrossRefPubMed Shin JY, Hwang JH, Jeong JY, Kim SH, Moon JD, Roh SC, Kim YW, Kim Y, Leem JH, Ju YS, Hong YS, Ha EH, Lee YH, Kim DH, Lee DH: The association of central obesity with type 2 diabetes among Koreans according to the serum gamma-glutamyltransferase level: Korean genome and epidemiology study. J Prev Med Public Health. 2009, 42: 386-391.CrossRefPubMed
7.
go back to reference Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR: A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem. 2007, 53: 1092-1098.CrossRefPubMed Lim JS, Lee DH, Park JY, Jin SH, Jacobs DR: A strong interaction between serum gamma-glutamyltransferase and obesity on the risk of prevalent type 2 diabetes: results from the Third National Health and Nutrition Examination Survey. Clin Chem. 2007, 53: 1092-1098.CrossRefPubMed
8.
go back to reference Fujita M, Ueno K, Hata A: Association of gamma-glutamyltransferase with incidence of type 2 diabetes in Japan. Exp Biol Med (Maywood). 2010, 235: 335-341.CrossRef Fujita M, Ueno K, Hata A: Association of gamma-glutamyltransferase with incidence of type 2 diabetes in Japan. Exp Biol Med (Maywood). 2010, 235: 335-341.CrossRef
9.
go back to reference Meisinger C, Lowel H, Heier M, Schneider A, Thorand B: Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med. 2005, 258: 527-535.CrossRefPubMed Meisinger C, Lowel H, Heier M, Schneider A, Thorand B: Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med. 2005, 258: 527-535.CrossRefPubMed
10.
go back to reference Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M: Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003, 49: 1358-1366.CrossRefPubMed Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M: Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003, 49: 1358-1366.CrossRefPubMed
11.
go back to reference Association Diabetes Association: Standards of medical care in diabetes--2013. Diabetes Care. 2013, 36 (Suppl 1): S11-S66.CrossRef Association Diabetes Association: Standards of medical care in diabetes--2013. Diabetes Care. 2013, 36 (Suppl 1): S11-S66.CrossRef
12.
go back to reference Nakanishi N, Nakamura K, Suzuki K, Tatara K: Lifestyle and the development of increased serum gamma-glutamyltransferase in middle-aged Japanese men. Scand J Clin Lab Invest. 2000, 60: 429-438.CrossRefPubMed Nakanishi N, Nakamura K, Suzuki K, Tatara K: Lifestyle and the development of increased serum gamma-glutamyltransferase in middle-aged Japanese men. Scand J Clin Lab Invest. 2000, 60: 429-438.CrossRefPubMed
13.
go back to reference Ministry for Health and welfare affairs Kcfdcap: Guideline for use of KNHANES. 2012 Ministry for Health and welfare affairs Kcfdcap: Guideline for use of KNHANES. 2012
14.
go back to reference Persijn JP, van der Slik W: A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem. 1976, 14: 421-427.PubMed Persijn JP, van der Slik W: A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem. 1976, 14: 421-427.PubMed
15.
go back to reference Kawamoto R, Tabara Y, Kohara K, Miki T, Ohtsuka N, Kusunoki T, Takayama S, Abe M: Serum gamma-glutamyl transferase within its normal concentration range is related to the presence of impaired fasting glucose and diabetes among Japanese community-dwelling persons. Endocr Res. 2011, 36: 64-73.CrossRefPubMed Kawamoto R, Tabara Y, Kohara K, Miki T, Ohtsuka N, Kusunoki T, Takayama S, Abe M: Serum gamma-glutamyl transferase within its normal concentration range is related to the presence of impaired fasting glucose and diabetes among Japanese community-dwelling persons. Endocr Res. 2011, 36: 64-73.CrossRefPubMed
16.
go back to reference Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med. 2003, 254: 287-295.CrossRefPubMed Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med. 2003, 254: 287-295.CrossRefPubMed
17.
go back to reference Shin JY, Lim JH, Koh DH, Kwon KS, Kim YK, Kim HC, Lee YC, Lee JH, Nam MS, Hong SB, Park SG: [Serum gamma-glutamyltransferase levels and the risks of impaired fasting glucose in healthy men: a 2-year follow-up]. J Prev Med Public Health. 2006, 39: 353-358.PubMed Shin JY, Lim JH, Koh DH, Kwon KS, Kim YK, Kim HC, Lee YC, Lee JH, Nam MS, Hong SB, Park SG: [Serum gamma-glutamyltransferase levels and the risks of impaired fasting glucose in healthy men: a 2-year follow-up]. J Prev Med Public Health. 2006, 39: 353-358.PubMed
18.
go back to reference Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50: 1844-1850.CrossRefPubMed Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50: 1844-1850.CrossRefPubMed
19.
go back to reference Lee DH, Blomhoff R, Jacobs DR: Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res. 2004, 38: 535-539.CrossRefPubMed Lee DH, Blomhoff R, Jacobs DR: Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res. 2004, 38: 535-539.CrossRefPubMed
20.
go back to reference Lee DH, Jacobs DR: Is serum gamma-glutamyltransferase a marker of exposure to various environmental pollutants?. Free Radic Res. 2009, 43: 533-537.CrossRefPubMed Lee DH, Jacobs DR: Is serum gamma-glutamyltransferase a marker of exposure to various environmental pollutants?. Free Radic Res. 2009, 43: 533-537.CrossRefPubMed
21.
go back to reference Yu AS, Keeffe EB: Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?. Am J Gastroenterol. 2003, 98: 955-956.CrossRefPubMed Yu AS, Keeffe EB: Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?. Am J Gastroenterol. 2003, 98: 955-956.CrossRefPubMed
22.
go back to reference Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24: 816-823.CrossRefPubMed Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24: 816-823.CrossRefPubMed
23.
go back to reference Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114: 1752-1761.CrossRefPubMedPubMedCentral Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004, 114: 1752-1761.CrossRefPubMedPubMedCentral
24.
go back to reference Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem. 2006, 52: 601-623.CrossRefPubMed Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem. 2006, 52: 601-623.CrossRefPubMed
25.
go back to reference Airaksinen R, Rantakokko P, Eriksson JG, Blomstedt P, Kajantie E, Kiviranta H: Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care. 2011, 34: 1972-1979.CrossRefPubMedPubMedCentral Airaksinen R, Rantakokko P, Eriksson JG, Blomstedt P, Kajantie E, Kiviranta H: Association between type 2 diabetes and exposure to persistent organic pollutants. Diabetes Care. 2011, 34: 1972-1979.CrossRefPubMedPubMedCentral
26.
go back to reference Gasull M, Pumarega J, Tellez-Plaza M, Castell C, Tresserras R, Lee DH, Porta M: Blood concentrations of persistent organic pollutants and prediabetes and diabetes in the general population of Catalonia. Environ Sci Technol. 2012, 46: 7799-7810.CrossRefPubMed Gasull M, Pumarega J, Tellez-Plaza M, Castell C, Tresserras R, Lee DH, Porta M: Blood concentrations of persistent organic pollutants and prediabetes and diabetes in the general population of Catalonia. Environ Sci Technol. 2012, 46: 7799-7810.CrossRefPubMed
27.
go back to reference Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, Jacobs DR: A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care. 2006, 29: 1638-1644.CrossRefPubMed Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, Jacobs DR: A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care. 2006, 29: 1638-1644.CrossRefPubMed
28.
go back to reference Sims EA: Are there persons who are obese, but metabolically healthy?. Metabolism. 2001, 50: 1499-1504.CrossRefPubMed Sims EA: Are there persons who are obese, but metabolically healthy?. Metabolism. 2001, 50: 1499-1504.CrossRefPubMed
29.
go back to reference Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, Engelgau MM, Vinicor F: Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care. 2004, 27: 2806-2812.CrossRefPubMed Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, Engelgau MM, Vinicor F: Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care. 2004, 27: 2806-2812.CrossRefPubMed
30.
go back to reference McLaughlin T, Abbasi F, Lamendola C, Reaven G: Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007, 167: 642-648.CrossRefPubMed McLaughlin T, Abbasi F, Lamendola C, Reaven G: Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007, 167: 642-648.CrossRefPubMed
31.
go back to reference Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M: Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004, 39: 754-763.CrossRefPubMed Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M: Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004, 39: 754-763.CrossRefPubMed
Metadata
Title
Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: a cross-sectional study
Authors
Nam Soo Hong
Jeong-Gook Kim
Yu-Mi Lee
Hyun-Woo Kim
Sin Kam
Keon-Yeop Kim
Ki-Su Kim
Duk-Hee Lee
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2014
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-14-57

Other articles of this Issue 1/2014

BMC Endocrine Disorders 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.